Megarebound könnte folgen wenn..

schöner Turnaround, mit wirklich guten Käufen zum Tagesende, wunderbar zu sehen im Chart,

steigende Kurse, bei steigendem Volumen,

es wird ein Kinderspiel den Dollar wiederzusehen,
am Dienstag ist die Konferenz, das treibt den Kurs von ganz allein,
kommen gute News sind die 1,50 USD bis nächsten Freitag auf jedenfall drin,

kommen die Interims (geh ich eher nicht von aus) und sind diese positiv sehen wir die 3 USD in no time, kommen keine News sind wir wieder bei 0,64 USD

wer schnelle 30 % machen will sollte jetzt rein, aber bitte in USA!!!

 

 

Gestern war die Konferenz, SUMMARY:

ANDES Interim Results werden early in Q2 erwartet, tippe auf etwa Mitte April
es gibt bereits Verhandlungen mit möglichen Partnern, zum Vertragsabschluss kommt es jedoch erst nach erfolgreichen Interims...(Partner könnten sein: PFIZER, Astra Zeneca u.a.)

Denke wir werden gute Ergebnisse bekommen und den Kurs von da an, nicht unter 3 USD sehen

MAKE OR BREAK jetzt zählts!

 

Hi,melde mich mal wieder als Vollinvestierter!

Sag mal,ist nicht die tatsache,das diabeteserkrankungswarscheinlichkeit um 60% gesenkt werden konnte (wie wird sowas ermittelt?) schon ein erfogreiches Interim result ???

MFG
Chali  

man näheres weiß. Danke für die Termin-Info, Andreano. Bei allem anderen wär ich bitteschön vorsichtig.
Momentan ist auch der Kurs alles andere als erwartungsfroh.  

....etwa die Ruhe vor dem Sturm?  

für meinen geschmack zu ruhig. gibts hier noch investierte? gehe davon aus dass der kurs diese woche noch etwas anzieht. anfang april sollten die Interim Results kommen.  

sieht doch absolut positiv aus...  

da geht heute aber was! werden recht große blöcke gekauft.  

könnte ich mir vorstellen dass es der Beginn eines Aufwärtstrends im Chart werden könnte. Was meint Ihr?  

 

 

nen Vorschlag?
Ne ich hab wirklich 80.  

 

 

 

ist schon ein wichtiges Signal.
Es muss ja nicht gleich der Dollar noch am selben Abend folgen :-)  Morgen ist auch noch ein Tag.
Volumen sah auch gut aus.
Hier kommt vielleicht was.  

könnte spannend werden! mir ist nicht klar, warum hier einige zu KERYX BIOPH. abgewandert sind?  

denn beide Aktien bieten gute Chancen auf Gewinne also sollte man beide im Depot haben.

Aber es gibt ja so viele Aktien die momentan gut erscheinen nur bei vielen ist das Geld zum investieren halt begrenzt wie bei mir und deshalb versucht man sich das Beste raus zu suchen.

Biotech ganz klar AGIX und KERX

Solarbereich ganz klar CSIQ,SOLF und JASO

Finanzbereich (sehr spekulativ) für mich ganz klar SPF,CFC,ABK,RHD,WCI,TMA

Hightech für mich momentan AAPL

Rüstungsindustrie für mich FRPT,SWHC


So siehts bei mir aus mehr geht halt nicht.  

ist grad in der ganz heißen phase. die ANDES Interim Results können täglich kommen. dienstag ist bei AGIX newstag.  

Entry into a Material Definitive Agreement


Item 1.01. Entry into a Material Definitive Agreement.

On April 1, 2008, AtheroGenics, Inc. (the "Company") entered into a Manufacturing and Supply Agreement (the "Agreement") with ISP Pharma Systems LLC ("ISP") for the manufacture and supply of the active pharmaceutical ingredient and an intermediate product (the "Product") of the Company's product candidate, AGI-1067. AGI-1067 is an investigational oral drug with anti-inflammatory and antioxidant properties that is being studied to determine its ability to improve glycemic control (blood sugar levels) in patients with diabetes.

The initial term of the Agreement expires on April 1, 2013 and the Agreement is automatically extended for successive two year terms thereafter if neither the Company nor ISP gives notice of non-renewal 180 days prior to the expiration of the initial or renewal term.

Under the terms of the Agreement, ISP has agreed to purchase certain equipment used in the manufacture of the Product from the Company, and to produce initial batches of the Product, if the Company elects to continue development of AGI-1067 after completion of an on-going clinical trial. The Company has agreed to pay ISP a specified fee for this work. In addition, ISP has agreed to supply, and the Company has agreed to purchase, specified percentages, which change over time, of the worldwide production requirements for the Product. The Company will pay ISP a specified purchase price, which varies based on annual quantities of the Product supplied. This purchase price is adjustable based on any changes in Product specifications mandated by the Company, and, following the end of each contract year, based upon certain industry price indices.

The Agreement also contains certain provisions regarding the rights and responsibilities of the parties with respect to manufacturing specifications, forecasting and ordering, delivery arrangements, payment terms, change orders, intellectual property rights, confidentiality and indemnification, as well as other customary terms and provisions.

The foregoing summary is qualified in its entirety by reference to the Agreement, which will be attached as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008.

The Company intends to submit a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Agreement. The omitted material will be included in the request for confidential treatment.  

Was heißt das für uns ?  

 

von der Webseite www.atherogenics.com
:

AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
Company to Host Conference Call and Webcast on April 14, 2008 at 9 a.m. EDT
ATLANTA, GA -- (MARKET WIRE) -- 04/14/2008 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today released topline results from a planned interim analysis of its ongoing ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type 2 diabetes. ANDES is evaluating two dose levels of AGI-1067 given once daily over six months. The primary efficacy endpoint is changed in hemoglobin A1c (A1c) from baseline compared to placebo in patients with Type 2 diabetes.

The interim analysis of 806 patients who completed three months in the study showed dose-related, statistically significant reductions in A1c. The mean changes for patients in the 150 mg, 75 mg, and placebo arms were 0.5 percent, 0.3 percent, and 0.1 percent respectively, (p < 0.001 for 150 mg versus placebo, p=0.001 for 75 mg versus placebo).

"The ANDES trial is ongoing and we must await final data before drawing firm conclusions," commented Alexander Fleming, M.D., Acting Chief Medical Officer. "We are encouraged by these early results, which show a meaningful reduction in blood sugar for patients with diabetes taking AGI-1067. The interim data also suggest that this three month assessment may not be capturing the full effect of AGI-1067 on A1c reduction, which is the standard clinical measure of blood sugar control."

"These interim results reinforce our belief that AGI-1067 may have the potential to introduce a new therapeutic approach for the treatment of patients with diabetes," said Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer at AtheroGenics. "We believe these results are sufficiently promising to allow for the planning of a second registration study. We plan to work with the FDA to gain their concurrence on the design of the next study."

Based on a preliminary review of the safety data, AGI-1067 was well-tolerated. The interim analysis showed no difference in discontinuations between groups receiving active drug and placebo. There has been one unexplained case of elevated liver enzymes greater than five times the upper limit of normal in each of the drug arms. These cases consisted only of moderate enzyme elevations without increases in bilirubin. The liver enzyme elevations either have resolved or are resolving. Because of the small number of these incidents, no conclusions should be drawn regarding AGI-1067's effect on the liver in the ANDES study until final data are available. An independent Data Safety and Monitoring Board recently reviewed these and other data from the clinical trial and recommended that the trial continue to completion.

ANDES Trial Design

The primary endpoint of ANDES (AGI-1067 as a Novel anti-Diabetic agent Evaluation Study) is an improvement in A1c at six months, evaluating two doses of AGI-1067 (75 mg and 150 mg) compared to placebo, on a background of one or no other oral anti-diabetes medicines. A total of 999 patients were enrolled in the ANDES study, including 887 in the current three-arm protocol. The pre-planned interim analysis measured A1c levels in at least ninety percent of ANDES patients when they had completed three months of dosing. Final results of the study are expected in the second half of this year.

About AGI-1067

AGI-1067 is novel oral drug candidate with demonstrated anti-inflammatory and antioxidant properties. AGI-1067 works by selectively inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli. Oxidative stress and inflammation have been implicated as playing a key role in the pathogenesis of insulin resistance and diabetes.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Teleconference and Webcast

AtheroGenics will host a conference call on Monday, April 14, 2008 at 9:00 a.m. Eastern Daylight Time to discuss the top-line interim results of the ANDES Phase 3 clinical trial.


   Conference Call Details:
   Dial-In:
   (877) 407-8031 (U.S.)
   (201) 689-8031 (International)
   To access the conference call replay, please dial (877) 660-6853 (U.S.)
   or (201) 612-7415 (International), Conference ID: 281135; Account #286.
   The conference call replay will be available through May 13, 2008.

   Webcast:
   To access the webcast, please go to
   http://www.atherogenics.com/investor/index.html.
   The webcast will be available through May 13, 2008 on AtheroGenics'
   website www.atherogenics.com.
Disclosure Regarding Forward-Looking Statements

Statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. Examples of forward looking statements in this press release include (i) our expectation that the interim analysis may not be capturing the full effect of AGI-1067 on A1c reduction, (ii) our belief that AGI-1067 may have the potential to introduce a new therapeutic approach for the treatment of patients with diabetes, and (iii) our expectation that final study results will be available in the second half of 2008. These and other such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. For example, additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. The U.S. Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.



CONTACTS:

AtheroGenics, Inc.
Mark P. Colonnese
Executive Vice President
678-336-2511
Email Contact

Media Inquiries
Jayme Maniatis / Dana Conti
Schwartz Communications, Inc.
781-684-0770
Email Contact

Investor Inquiries
Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
Email Contact  

das sieht doch danz gut aus, wollen wir hoffen, dass es weiter nach oben geht und die neuen medikamente die zulassung bekommen